SCHEMBL6410235

SCHEMBL6410235

CN1C(=O)c2ccccc2C(C(=O)Nc2nccs2)C1c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.46
ALDH1A1 P00352 3/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TSHR P16473 1/20 0.45
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
EGFR P00533 1/20 0.41
KDR P35968 1/20 0.41
HPGD P15428 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GRM1 Q13255 1/20 0.40
GLA P06280 1/20 0.40
CASP1 P29466 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6410230 1.00 HSD17B10 (0.46) HSD17B10ALDH1A1MAPTKDM4EGAA
SCHEMBL6417689 0.88 GAA (0.45) HSD17B10ALDH1A1MAPTKDM4EGAA
SCHEMBL6410777 0.87 GAA (0.48) HSD17B10ALDH1A1MAPTKDM4EGAA
SCHEMBL6410790 0.85 GAA (0.46) HSD17B10ALDH1A1MAPTKDM4EGAA
SCHEMBL6413221 0.85 CYP1A2 (0.55) HSD17B10ALDH1A1MAPTKDM4EGAA
SCHEMBL6413117 0.85 CYP2C9 (0.51) HSD17B10ALDH1A1MAPTKDM4EGAA
SCHEMBL6410201 0.84 GAA (0.52) HSD17B10ALDH1A1MAPTKDM4EGAA
SCHEMBL6413440 0.84 GAA (0.51) HSD17B10ALDH1A1MAPTKDM4EGAA
SCHEMBL6419719 0.83 HSD17B10 (0.50) HSD17B10ALDH1A1MAPTKDM4EGAA
SCHEMBL6410788 0.83 GAA (0.51) HSD17B10ALDH1A1MAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD HSD17B10 1460/4885ALDH1A1 1368/4885MAPT 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.